Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group

R C Sachdeo1, R F Leroy, G L Krauss

  • 1Department of Neurology, University of Medicine and Dentistry of New Jersey, New Brunswick 08901-2160, USA.

Archives of Neurology
|May 1, 1997
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of the haemophilia A mutation in sporadic patients registered at the Royal London Hospital and their families.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.

Acta neurologica Scandinavica·2012
Same author

The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory.

Epilepsy & behavior : E&B·2012
Same author

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Neurology·2012
Same author

Lacosamide for the treatment of epilepsy.

Annals of medicine·2012
Same author

Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs.

Journal of veterinary internal medicine·2012

Tiagabine effectively reduced complex partial seizures (CPSs) in patients with refractory epilepsy. Both 2-times-daily and 4-times-daily regimens were well-tolerated, showing significant seizure reduction compared to placebo.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy is a neurological disorder characterized by recurrent seizures.
  • Complex partial seizures (CPSs) often require add-on pharmacotherapy when initial treatments fail.

Purpose of the Study:

  • To assess the efficacy and safety of two tiagabine dosing regimens as adjunctive therapy for refractory CPSs.
  • To compare tiagabine's effectiveness against placebo in a randomized, double-blind trial.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 318 patients with refractory CPSs.
  • Patients received either tiagabine (16 mg BID or 8 mg QID) or placebo for 12 weeks.
  • The primary outcome measure was the change in 4-week CPS frequency from baseline.

Main Results:

Related Experiment Videos

  • Tiagabine significantly reduced seizure frequency compared to placebo (P=.02 for 16mg BID, P=.06 for 8mg QID).
  • A 50% or greater seizure reduction was achieved in 31% (16mg BID) and 27% (8mg QID) of patients, versus 10% for placebo (P<.001).
  • Adverse events, primarily CNS-related, were comparable across groups, with similar discontinuation rates.

Conclusions:

  • Tiagabine, as add-on therapy, is effective in reducing CPS frequency in treatment-refractory epilepsy.
  • Both tested tiagabine regimens demonstrated good tolerability and safety profiles.